Navigation Links
Baxter Raises Full-Year 2008 Outlook Following Strong Second-Quarter Financial Results
Date:7/17/2008

638 661

--------------------------------------------------------------------------

ADJUSTED PRE-TAX INCOME (excluding

specified item) $672 $578 (3) 16%

ADJUSTED NET INCOME (excluding

specified item) $544 $477 (3) 14%

ADJUSTED DILUTED EPS (excluding

specified item) $0.85 $0.72 (3) 18%

(1) A restructuring charge of $70 million ($46 million, or $0.07 per

share, on an after-tax basis) in 2007 was primarily for costs and

asset impairments associated with the consolidation of certain

commercial and manufacturing operations outside of the United States.

(2) Income tax expense in 2007 included a $15 million benefit related to

an audit settlement and the extension of tax incentives in

jurisdictions outside the United States. The effective income tax

rate in 2007 was also favorably impacted by the restructuring charge

described in Note 1 above.

(3) Refer to page 6 for a description of the adjustment and a

reconciliation to GAAP (generally accepted accounting principles)

measures.

Non-GAAP Financial Measures: The non-GAAP financial measures contained in

this press release (pre-tax income, net income and per-share earnings,

excluding certain items) adjust for factors that are unusual or

nonrecurring. Unusual or nonrecurring items can be highly variable,

difficult to predict, and of a size that may substantially impact the

company's reported operations for a period. Management believes that non-

GAAP financial measures can facilitate a fuller analysis of the company's

results of operations, particularly in evaluating performance period over

period. Management uses these non-GAAP financial measures internally in

financial pl
'/>"/>

SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related biology technology :

1. Bioniche Pharma Acquires Baxters ENLON(R) and ENLON-PLUS(R)
2. Baxters Board of Directors Declares Quarterly Dividend
3. Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook
4. Baxters V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals
5. Baxter Announces FDA Approval of ARTISS Slow-Setting Fibrin Sealant in Treatment of Burn Patients
6. Baxters Board of Directors Approves New Share Repurchase Authorization of $2 Billion
7. Baxter and Its Foundation Contribute Nearly $53 Million in 2007 to Address Critical Needs Locally and Globally
8. Baxter to Proceed With Recall of Remaining Heparin Sodium Vial Products
9. Baxter Declares Quarterly Dividend
10. Baxter Provides Update on Heparin Reactions
11. Baxters Costa Rica Facility Recognized With Shingo Prize for Excellence in Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015  Neurotech Pharmaceuticals, ... enrolled in the multicenter Phase 2 clinical trial ... long-term treatment of recurrent subfoveal choroidal neovascularization secondary ... is a unique vascular endothelial growth factor (VEGF) ... implant. "This landmark proof-of-concept study will ...
(Date:9/2/2015)... 2015 BioLight Life Sciences ... "Company"), a firm that invests in, manages and ... announced today that presentations highlighting its IOPtiMate™ system ... at the Ophthalmology Futures European Forum and the ... & Refractive Surgeons ("ESCRS"), both taking place in ...
(Date:9/2/2015)... ... September 02, 2015 , ... Whitehouse Laboratories is ... attending Pharma Ed Resources upcoming educational seminar and training session on Extractable & ... timely conference will provide Updates & Case Studies on the Latest Compliance Implications ...
(Date:9/1/2015)... , September 2, 2015 ... auf die Forschung und Entwicklung neuartiger Therapien ... chronisch-entzündliche Darmerkrankungen und Reizdarm konzentriert, erhält vom ... dass sein neues Medikament patentiert wird. Das ... Allergien bei Kindern verhindert und Entzündungen vorbeugt.   ...
Breaking Biology Technology:Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3Das Patent von Swecure zur Verhinderung von Allergien bei Kindern wird in den USA zugelassen 2
... EMERYVILLE, Calif., Nov. 4 Onyx Pharmaceuticals, Inc. (Nasdaq: ... at the Credit Suisse 18th Annual Healthcare Conference on ... a.m. Pacific Time). Interested parties may access a ... http://www.onyx-pharm.com/view.cfm/32/Event-Calendar , It is recommended ...
... BOZEN, Italy, November 4 Health Robotics ... i.v.SOFT Workflow Engine at,the American Society of Health-System Pharmacists, ... of the i.v.SOFT Workflow Engine,Health Robotics becomes the first ... automation solution to fill the void of automated process ...
... 4 ThromboGenics NV,(Euronext Brussels: THR), a biopharmaceutical company focused ... today issuing a,business update for the period ending 30 September, ... of ThromboGenics, said: , "ThromboGenics, clinical ... happy to have completed patient enrolment,for the US Phase III ...
Cached Biology Technology:Health Robotics Announces December Launch of the i.v.SOFT(TM) Workflow Engine at ASHP in Las Vegas 2Health Robotics Announces December Launch of the i.v.SOFT(TM) Workflow Engine at ASHP in Las Vegas 3ThromboGenics NV - Q3 2009 Business Update 2ThromboGenics NV - Q3 2009 Business Update 3ThromboGenics NV - Q3 2009 Business Update 4ThromboGenics NV - Q3 2009 Business Update 5ThromboGenics NV - Q3 2009 Business Update 6ThromboGenics NV - Q3 2009 Business Update 7
(Date:8/18/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/9dmm6l/global_biometric ... "Global Biometric Authentication & Identification Market: Focus On ... 2015-2020" report to their offering. ... market is expected to grow at an estimated ... generate over $25 billion (approximately) by 2020 as ...
(Date:8/12/2015)... , August 12, 2015 As ... mobile payment innovation and advanced biometrics technology is accelerating ... way consumers rely on using their credit cards, the ... the future for payment services led by companies in ... ), :  Google, Inc. (NASDAQ: GOOG ), Apple ...
(Date:8/11/2015)... GOTHENBURG, Sweden , August 11, 2015 ... sensor FPC1155. Already received as well as expected revenues in 2015 ... included in FPC,s communicated revenue guidance of approximately 2,200 MSEK for ... is a prominent smartphone manufacturer ... ZUK selected FPC1 155 ...
Breaking Biology News(10 mins):Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2
... may not be enough to experience significant health benefits, ... activity such as walking alone is not likely going ... that occasionally elevate the intensity," said Dr. Vicki Harber, ... presented recently at the American College of Sports Medicine ...
... sepsis, a fast-moving blood infection that is a leading ... illness unleashes a powerful inflammatory response that can quickly ... within days. , With a narrow window of opportunity ... typically rush to prescribe powerful antibiotics, even before laboratory ...
... complete with her brood of some 20 eggs and 2 ... part anatomy including legs and eyes. , The research team ... Siveter from Oxford, Mark Sutton from Imperial College London and ... made a digital image of the fossil - an ostracod ...
Cached Biology News:Walking not enough for significant exercise benefits 2Gene chip technology shows potential for identifying life-threatening blood infection 2Gene chip technology shows potential for identifying life-threatening blood infection 3Gene chip technology shows potential for identifying life-threatening blood infection 4
ANTI S. ENTERID LPS...
B.D. Hames and D.M. Glover (1996) • This issue covers T-Cell antigen receptor genes; T-Lymphocyte signal transduction; B-Cell activation antibody engineering and the complement system and other ...
Request Info...
RABBIT ANTI PORCINE CARBOXYPEPTIDASE B...
Biology Products: